Multiple muscarinic acetylcholine receptor subtypes modulate striatal dopamine release, as studied with M1-M5 muscarinic receptor knock-out mice.
paper
Cited
Public
Unavailable
- Authors
- Zhang, Weilie; Yamada, Masahisa; Gomeza, Jesus; Basile, Anthony S; Wess, JΓΌrgen
- Year
- 2002
- Journal
- The Journal of neuroscience : the official journal of the Society for Neuroscience
- PMID
- 12151512
- DOI
- 10.1523/JNEUROSCI.22-15-06347.2002
- PMCID
- PMC6758135
A proper balance between striatal muscarinic cholinergic and dopaminergic neurotransmission is required for coordinated locomotor control. Activation of striatal muscarinic acetylcholine receptors (mAChRs) is known to modulate striatal dopamine release. To identify the mAChR subtype(s) involved in this activity, we used genetically altered mice that lacked functional M1-M5 mAChRs [knock-out (KO) mice]. In superfused striatal slices from wild-type mice, the non-subtype-selective muscarinic agonist oxotremorine led to concentration-dependent increases in potassium-stimulated [3H]dopamine release (by up to 60%). The lack of M1 or M2 receptors had no significant effect on the magnitude of these responses. Strikingly, oxotremorine-mediated potentiation of stimulated striatal [3H]dopamine release was abolished in M4 receptor KO mice, significantly increased in M3 receptor-deficient mice, and significantly reduced (but not abolished) in M5 receptor KO mice. Additional release studies performed in the presence of tetrodotoxin suggested that the dopamine release-stimulating M4 receptors are probably located on neuronal cell bodies, but that the release-facilitating M5 and the release-inhibiting M3 receptors are likely to be located on nerve terminals. Studies with the GABA(A) receptor blocker bicuculline methochloride suggested that M3 and M4 receptors mediate their dopamine release-modulatory effects via facilitation or inhibition, respectively, of striatal GABA release. These results provide unambiguous evidence that multiple mAChR subtypes are involved in the regulation of striatal dopamine release. These findings should contribute to a better understanding of the important functional roles that the muscarinic cholinergic system plays in striatal function.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Exploring Adjunctive Novel Therapeutic Approach of KarXT (Xanomeline-Trospium Chloride) for Managing Psychotic Symptoms in Patients With Schizophrenia and Alzheimer's Disease. | Kanwal A et al. | β | 2026 | β |
| M5 positive allosteric modulation alleviates parkinsonian motor deficits. | Chambers NE et al. | β | 2026 | β |
| The Acetylcholine Esterase Inhibitor Donepezil Increases Dopamine Levels in the Nucleus Accumbens and Blocks the Alcohol Deprivation Effect in Rats. | LoftΓ©n A et al. | β | 2026 | β |
| Acute Hypobaric Hypoxia Causes Alterations in Acetylcholine-Mediated Signaling Through Varying Expression of Muscarinic Receptors in the Prefrontal Cortex and Cerebellum of Rats' Brain. | Sharma NK et al. | β | 2025 | β |
| Cholinergic system in schizophrenia: A systematic review and meta-analysis. | Saint-Georges Z et al. | β | 2025 | β |
| Does Dysregulation Of The Indirect Pathway Contribute To The Pathophysiology Of Catatonia Through Neurotransmitter Imbalance? | Seif P | β | 2025 | β |
| Novel opportunities for treating complex neuropsychiatric and neurocognitive conditions based on recent developments with xanomeline. | Pavlov VA | β | 2025 | β |
| Quantitative Systems Pharmacology Development and Application in Neuroscience. | Geerts H | β | 2025 | β |
| The Novel Functions of M4 Muscarinic Receptors. | Myslivecek J et al. | β | 2025 | β |
| Current Findings and Potential Mechanisms of KarXT (Xanomeline-Trospium) in Schizophrenia Treatment. | Azargoonjahromi A | β | 2024 | β |
| Dysregulated acetylcholine-mediated dopamine neurotransmission in the eIF4E Tg mouse model of autism spectrum disorders | Carbonell-Roig J et al. | β | 2024 | β |
| Dysregulated acetylcholine-mediated dopamine neurotransmission in the eIF4E Tg mouse model of autism spectrum disorders. | Carbonell-Roig J et al. | β | 2024 | β |
| Effects of Age and MPTP-Induced Parkinson's Disease on the Expression of Genes Associated with the Regulation of the Sleep-Wake Cycle in Mice. | Semenova EI et al. | β | 2024 | β |
| G protein-coupled receptor modulation of striatal dopamine transmission: Implications for psychoactive drug effects. | Littlepage-Saunders M et al. | β | 2024 | β |
| IUPHAR Review on muscarinic M1 and M4 receptors as drug treatment targets relevant to the molecular pathology of schizophrenia. | Dean B | β | 2024 | β |
| Potential of olfactory neuroepithelial cells as a model toΒ study schizophrenia: A focus on GPCRs (Review). | SΓ‘nchez-Florentino ZA et al. | β | 2024 | β |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Muscarinic M<sub>3</sub> Receptor-Positive Allosteric Modulator ASP8302 Following Single and Multiple Ascending Oral Doses in Healthy Volunteers. | Takusagawa S et al. | β | 2024 | β |
| Targeting muscarinic receptors for the treatment of alcohol use disorders: Opportunities and hurdles for clinical development. | Walker LC et al. | β | 2024 | β |
| Selective M<sub>5</sub> muscarinic acetylcholine receptor negative allosteric modulator VU6008667 blocks acquisition of opioid self-administration. | Teal LB et al. | β | 2023 | β |
| Blockade of M4 muscarinic receptors on striatal cholinergic interneurons normalizes striatal dopamine release in a mouse model of TOR1A dystonia. | Downs AM et al. | β | 2022 | β |
| Cannabis induced psychosis: A systematic review on the role of genetic polymorphisms. | Carvalho C et al. | β | 2022 | β |
| Chemogenetic activation of VGLUT3-expressing neurons decreases movement. | Kljakic O et al. | β | 2022 | β |
| Drug Design Targeting the Muscarinic Receptors and the Implications in Central Nervous System Disorders. | Johnson CR et al. | β | 2022 | β |
| Modulation of Muscarinic Signalling in the Central Nervous System by Steroid Hormones and Neurosteroids. | Szczurowska E et al. | β | 2022 | β |
| Striatal Synaptic Dysfunction in Dystonia and Levodopa-Induced Dyskinesia. | Scarduzio M et al. | β | 2022 | β |
| The effects of galangin in prepulse inhibition test and experimental schizophrenia models. | Kaygisiz B et al. | β | 2022 | β |
| An acetylcholine-dopamine interaction in the nucleus accumbens and its involvement in ethanol's dopamine-releasing effect. | LoftΓ©n A et al. | β | 2021 | β |
| CalDAG-GEFI mediates striatal cholinergic modulation of dendritic excitability, synaptic plasticity and psychomotor behaviors. | Crittenden JR et al. | β | 2021 | β |
| Increased Endogenous GDNF in Mice Protects Against Age-Related Decline in Neuronal Cholinergic Markers. | Mitra S et al. | β | 2021 | β |
| Sex differences in dopamine release regulation in the striatum. | Zachry JE et al. | β | 2021 | β |
| Therapeutic Potential of Multifunctional Derivatives of Cholinesterase Inhibitors. | PrzybyΕowska M et al. | β | 2021 | β |
| Two Players in the Field: Hierarchical Model of Interaction between the Dopamine and Acetylcholine Signaling Systems in the Striatum. | Myslivecek J | β | 2021 | β |
| Allosteric modulation of muscarinic receptors in alcohol and substance use disorders. | Walker LC et al. | β | 2020 | β |
| Conventional and Novel Pharmacological Approaches to Treat Dopamine-Related Disorders: Focus on Parkinson's Disease and Schizophrenia. | Perez de la Mora M et al. | β | 2020 | β |
| Fine Tuning Muscarinic Acetylcholine Receptor Signaling Through Allostery and Bias. | van der Westhuizen ET et al. | β | 2020 | β |
| Heterogeneity in striatal dopamine circuits: Form and function in dynamic reward seeking. | Collins AL et al. | β | 2020 | β |
| Striatal Dopamine D<sub>2</sub>-Muscarinic Acetylcholine M<sub>1</sub> Receptor-Receptor Interaction in a Model of Movement Disorders. | Crans RAJ et al. | β | 2020 | β |
| A regulatory variant of CHRM3 is associated with cannabis-induced hallucinations in European Americans. | Cheng Z et al. | β | 2019 | β |
| Beta-amyloid short- and long-term synaptic entanglement. | Lanni C et al. | β | 2019 | β |
| Cholinergic modulation of striatal microcircuits. | Abudukeyoumu N et al. | β | 2019 | β |
| Constitutional 763.3 Kb chromosome 1q43 duplication encompassing only CHRM3 gene identified by next generation sequencing (NGS) in a child with intellectual disability. | Cheng X et al. | β | 2019 | β |
| Eckol as a Potential Therapeutic against Neurodegenerative Diseases Targeting Dopamine Dβ/Dβ Receptors. | Paudel P et al. | β | 2019 | β |
| Increased Cholinergic Response in Ξ±-Synuclein Transgenic Mice (h-Ξ±-synL62). | KΓΆnig M et al. | β | 2019 | β |
| Is there a role for antibodies targeting muscarinic acetylcholine receptors in the pathogenesis of schizophrenia? | Ryan AE et al. | β | 2019 | β |
| Muscarinic agonist, (Β±)-quinuclidin-3-yl-(4-fluorophenethyl)(phenyl)carbamate: High affinity, but low subtype selectivity for human M<sub>1</sub> - M<sub>5</sub> muscarinic acetylcholine receptors. | Lee NR et al. | β | 2019 | β |
| Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders. | Quik M et al. | β | 2019 | β |
| Roles of the M<sub>4</sub> acetylcholine receptor in the basal ganglia and the treatment of movement disorders. | Moehle MS et al. | β | 2019 | β |
| Selective allosteric modulation of muscarinic acetylcholine receptors for the treatment of schizophrenia and substance use disorders. | Teal LB et al. | β | 2019 | β |
| Striatal Cholinergic Interneurons Are a Novel Target of Corticotropin Releasing Factor. | Lemos JC et al. | β | 2019 | β |
| The neurobiological basis for novel experimental therapeutics in dystonia. | Downs AM et al. | β | 2019 | β |
| The Pharmacology of Visual Hallucinations in Synucleinopathies. | Russo M et al. | β | 2019 | β |
| Trihexyphenidyl rescues the deficit in dopamine neurotransmission in a mouse model of DYT1 dystonia. | Downs AM et al. | β | 2019 | β |
| Widespread Changes in Positive Allosteric Modulation of the Muscarinic M1 Receptor in Some Participants With Schizophrenia. | Hopper S et al. | β | 2019 | β |
| Acetylcholine Neurotransmitter Receptor Densities in the Striatum of Hemiparkinsonian Rats Following Botulinum Neurotoxin-A Injection. | Mann T et al. | β | 2018 | β |
| Evolution in Neuromodulation-The Differential Roles of Acetylcholine in Higher Order Association vs. Primary Visual Cortices. | Galvin VC et al. | β | 2018 | β |
| Muscarinic receptor subtype distribution in the central nervous system and relevance to aging and Alzheimer's disease. | Lebois EP et al. | β | 2018 | β |
| Physiological roles of CNS muscarinic receptors gained from knockout mice. | Thomsen M et al. | β | 2018 | β |
| The striatal cholinergic system in L-dopa-induced dyskinesias. | Perez XA et al. | β | 2018 | β |
| Anticholinergic activity in the nervous system: Consequences for visuomotor function. | Naicker P et al. | β | 2017 | β |
| Cholinergic Projections to the Substantia Nigra Pars Reticulata Inhibit Dopamine Modulation of Basal Ganglia through the M<sub>4</sub> Muscarinic Receptor. | Moehle MS et al. | β | 2017 | β |
| Cholinergic System and Post-translational Modifications: An Insight on the Role in Alzheimer's Disease. | Ahmed T et al. | β | 2017 | β |
| Dynamic changes in murine forebrain miR-211 expression associate with cholinergic imbalances and epileptiform activity. | Bekenstein U et al. | β | 2017 | β |
| M<sub>1</sub> muscarinic activation induces long-lasting increase in intrinsic excitability of striatal projection neurons. | Lv X et al. | β | 2017 | β |
| Muscarinic receptor binding changes in postmortem Parkinson's disease. | McOmish C et al. | β | 2017 | β |
| Vesicular acetylcholine transporter (VAChT) over-expression induces major modifications of striatal cholinergic interneuron morphology and function. | Janickova H et al. | β | 2017 | β |
| A threshold model for opposing actions of acetylcholine on reward behavior: Molecular mechanisms and implications for treatment of substance abuse disorders. | Grasing K | β | 2016 | β |
| Pharmacological profile of N-(2,6-dichlorophenyl)-2-(4-methyl-1-piperidinyl)acetamide, a novel analogue of lidocaine. | DΓ©ciga-Campos M et al. | β | 2016 | β |
| Striatal dopamine neurotransmission: regulation of release and uptake. | Sulzer D et al. | β | 2016 | β |
| Changes in cholinergic and glutamatergic markers in the striatum from a sub-set of subjects with schizophrenia. | Dean B et al. | β | 2015 | β |
| Cholinergic interneurons in the dorsal and ventral striatum: anatomical and functional considerations in normal and diseased conditions. | Gonzales KK et al. | β | 2015 | β |
| Cholinergic Modulation of Stimulus-Specific Adaptation in the Inferior Colliculus. | Ayala YA et al. | β | 2015 | β |
| Loss of feedback inhibition via D2 autoreceptors enhances acquisition of cocaine taking and reactivity to drug-paired cues. | Holroyd KB et al. | β | 2015 | β |
| Omega-3 fatty acids prevent the ketamine-induced increase in acetylcholinesterase activity in an animal model of schizophrenia. | Zugno AI et al. | β | 2015 | β |
| Striatal cholinergic dysfunction as a unifying theme in the pathophysiology of dystonia. | Eskow Jaunarajs KL et al. | β | 2015 | β |
| Understanding responder neurobiology in schizophrenia using a quantitative systems pharmacology model: application to iloperidone. | Geerts H et al. | β | 2015 | β |
| Citicoline in addictive disorders: a review of the literature. | Wignall ND et al. | β | 2014 | β |
| Enhanced flexibility of place discrimination learning by targeting striatal cholinergic interneurons. | Okada K et al. | β | 2014 | β |
| M4 mAChR-mediated modulation of glutamatergic transmission at corticostriatal synapses. | Pancani T et al. | β | 2014 | β |
| Striatal cholinergic interneuron regulation and circuit effects. | Lim SA et al. | β | 2014 | β |
| Cholinergic connectivity: it's implications for psychiatric disorders. | Scarr E et al. | β | 2013 | β |
| Global actions of nicotine on the striatal microcircuit. | Plata V et al. | β | 2013 | β |
| Somatodendritic targeting of M5 muscarinic receptor in the rat ventral tegmental area: implications for mesolimbic dopamine transmission. | GarzΓ³n M et al. | β | 2013 | β |
| Structural modifications to tetrahydropyridine-3-carboxylate esters en route to the discovery of M5-preferring muscarinic receptor orthosteric antagonists. | Zheng G et al. | β | 2013 | β |
| The muscarinic acetylcholine receptor agonist BuTAC mediates antipsychotic-like effects via the M4 subtype. | Watt ML et al. | β | 2013 | β |
| Acetylcholine as a neuromodulator: cholinergic signaling shapes nervous system function and behavior. | Picciotto MR et al. | β | 2012 | β |
| Galantamine attenuates the heroin seeking behaviors induced by cues after prolonged withdrawal in rats. | Liu H et al. | β | 2012 | β |
| Muscarinic agonists and antagonists in schizophrenia: recent therapeutic advances and future directions. | Bolbecker AR et al. | β | 2012 | β |
| Muscarinic mechanisms in psychotic disorders. | McKinzie DL et al. | β | 2012 | β |
| Muscarinic modulation of striatal function and circuitry. | Goldberg JA et al. | β | 2012 | β |
| Muscarinic receptors acting at pre- and post-synaptic sites differentially regulate dopamine/DARPP-32 signaling in striatonigral and striatopallidal neurons. | Kuroiwa M et al. | β | 2012 | β |
| Novel muscarinic receptor mutant mouse models. | Wess J | β | 2012 | β |
| Presynaptic muscarinic M(2) receptors modulate glutamatergic transmission in the bed nucleus of the stria terminalis. | Guo JD et al. | β | 2012 | β |
| Regulation of striatal dopamine release by presynaptic auto- and heteroreceptors. | Zhang H et al. | β | 2012 | β |
| The pharmacology of McN-A-343. | Mitchelson FJ | β | 2012 | β |
| Control of striatal signaling by g protein regulators. | Xie K et al. | β | 2011 | β |
| Dopamine release in the basal ganglia. | Rice ME et al. | β | 2011 | β |
| Dopamine signaling in dorsal versus ventral striatum: the dynamic role of cholinergic interneurons. | Threlfell S et al. | β | 2011 | β |
| Impact of species variability and 'probe-dependence' on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor. | Suratman S et al. | β | 2011 | β |
| Muscarinic acetylcholine receptors in the nucleus accumbens core and shell contribute to cocaine priming-induced reinstatement of drug seeking. | Yee J et al. | β | 2011 | β |
| The Mβ/Mβ preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia. | Barak S et al. | β | 2011 | β |
| The receptor architecture of the pigeons' nidopallium caudolaterale: an avian analogue to the mammalian prefrontal cortex. | Herold C et al. | β | 2011 | β |
| Acetylcholine-dopamine interactions in the pathophysiology and treatment of CNS disorders. | Lester DB et al. | β | 2010 | β |
| AGAP1/AP-3-dependent endocytic recycling of M5 muscarinic receptors promotes dopamine release. | Bendor J et al. | β | 2010 | β |
| Altered neural cholinergic receptor systems in cocaine-addicted subjects. | Adinoff B et al. | β | 2010 | β |
| A subpopulation of neuronal M4 muscarinic acetylcholine receptors plays a critical role in modulating dopamine-dependent behaviors. | Jeon J et al. | β | 2010 | β |
| G protein-coupled receptor oligomerization for what? | Ciruela F et al. | β | 2010 | β |
| Interactions between morphine, scopolamine and nicotine: schedule-controlled responding in rats. | Li X et al. | β | 2010 | β |
| Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties. | Leach K et al. | β | 2010 | β |
| Pharmacological strategies for enhancing cognition in schizophrenia. | Barch DM | β | 2010 | β |
| Specific inhibitory effect of amyloid-beta on presynaptic muscarinic receptor subtypes modulating neurotransmitter release in the rat nucleus accumbens. | Grilli M et al. | β | 2010 | β |
| Striatal muscarinic receptors promote activity dependence of dopamine transmission via distinct receptor subtypes on cholinergic interneurons in ventral versus dorsal striatum. | Threlfell S et al. | β | 2010 | β |
| The M(5) muscarinic acetylcholine receptor third intracellular loop regulates receptor function and oligomerization. | Borroto-Escuela DO et al. | β | 2010 | β |
| [Characterization of muscarinic receptors in undifferentiated thyroid cells in Fisher rats]. | Botella Romero F et al. | β | 2009 | β |
| Combined scopolamine and ethanol treatment results in a locomotor stimulant response suggestive of synergism that is not blocked by dopamine receptor antagonists. | Scibelli AC et al. | β | 2009 | β |
| Components of lemon essential oil attenuate dementia induced by scopolamine. | Zhou W et al. | β | 2009 | β |
| Effects of scopolamine on dopamine neurons in the substantia nigra: role of the pedunculopontine tegmental nucleus. | Di Giovanni G et al. | β | 2009 | β |
| Gain of new exons and promoters by lineage-specific transposable elements-integration and conservation event on CHRM3 gene. | Huh JW et al. | β | 2009 | β |
| Identification of an Ascaris G protein-coupled acetylcholine receptor with atypical muscarinic pharmacology. | Kimber MJ et al. | β | 2009 | β |
| Primary dystonia: molecules and mechanisms. | Tanabe LM et al. | β | 2009 | β |
| Sedation and antinociception induced by a new pyrazolo[3,4-b]pyrrolo[3,4-d]pyridine derivative (LASSBio-873) is modulated by activation of muscarinic receptors. | Mendes TC et al. | β | 2009 | β |
| The M5 muscarinic receptor as possible target for treatment of drug abuse. | Raffa RB | β | 2009 | β |
| Acute beta-amyloid administration disrupts the cholinergic control of dopamine release in the nucleus accumbens. | Preda S et al. | β | 2008 | β |
| Anatomy, function and regulation of neuropeptide EI (NEI). | Bittencourt J et al. | β | 2008 | β |
| A Role for Adenosine A1 Receptors in GABA and NMDA-Receptor Mediated Modulation of Dopamine Release: Studies Using Fast Cyclic Voltammetry. | O'Connor JJ et al. | β | 2008 | β |
| Chronic treatment with simvastatin upregulates muscarinic M1/4 receptor binding in the rat brain. | Wang Q et al. | β | 2008 | β |
| Comparison of systemic and local methamphetamine treatment on acetylcholine and dopamine levels in the ventral tegmental area in the mouse. | Dobbs LK et al. | β | 2008 | β |
| Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia? | Scarr E et al. | β | 2008 | β |
| Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. | Jones CK et al. | β | 2008 | β |
| Presynaptic metabotropic receptors for acetylcholine and adrenaline/noradrenaline. | Gilsbach R et al. | β | 2008 | β |
| Presynaptic nicotinic receptors: a dynamic and diverse cholinergic filter of striatal dopamine neurotransmission. | Exley R et al. | β | 2008 | β |
| Release-enhancing pre-synaptic muscarinic and nicotinic receptors co-exist and interact on dopaminergic nerve endings of rat nucleus accumbens. | Grilli M et al. | β | 2008 | β |
| The role of acetylcholine in cocaine addiction. | Williams MJ et al. | β | 2008 | β |
| Ultrasonic vocalizations induced by sex and amphetamine in M2, M4, M5 muscarinic and D2 dopamine receptor knockout mice. | Wang H et al. | β | 2008 | β |
| Decreased prepulse inhibition and increased sensitivity to muscarinic, but not dopaminergic drugs in M5 muscarinic acetylcholine receptor knockout mice. | Thomsen M et al. | β | 2007 | β |
| Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. | Armbruster BN et al. | β | 2007 | β |
| Involvement of KCNQ2 subunits in [3H]dopamine release triggered by depolarization and pre-synaptic muscarinic receptor activation from rat striatal synaptosomes. | Martire M et al. | β | 2007 | β |
| Muscarinic acetylcholine receptor subtype expression in avian vestibular hair cells, nerve terminals and ganglion cells. | Li GQ et al. | β | 2007 | β |
| Towards a muscarinic hypothesis of schizophrenia. | Raedler TJ et al. | β | 2007 | β |
| Glial cell line-derived neurotrophic factor (GDNF) enhances dopamine release from striatal nerve endings in an adenosine A2A receptor-dependent manner. | Gomes CA et al. | β | 2006 | β |
| Injection of oxotremorine in nucleus accumbens shell reduces cocaine but not food self-administration in rats. | Mark GP et al. | β | 2006 | β |
| The selective m1 muscarinic antagonist MT-7 blocks pilocarpine-induced striatal Fos expression. | Wirtshafter D | β | 2006 | β |
| An investigation of whether agonist-selective receptor conformations occur with respect to M2 and M4 muscarinic acetylcholine receptor signalling via Gi/o and Gs proteins. | Mistry R et al. | β | 2005 | β |
| Cholinergic suppression of KCNQ channel currents enhances excitability of striatal medium spiny neurons. | Shen W et al. | β | 2005 | β |
| Distinct mixtures of muscarinic receptor subtypes mediate inhibition of noradrenaline release in different mouse peripheral tissues, as studied with receptor knockout mice. | Trendelenburg AU et al. | β | 2005 | β |
| Gi/Go protein-dependent presynaptic mechanisms are involved in clozapine-induced down-regulation of tyrosine hydroxylase in PC12 cells. | Tejedor-Real P et al. | β | 2005 | β |
| Intrastriatal dopamine D1 receptor agonist-mediated motor behavior is reduced by local neurokinin 1 receptor antagonism. | Krolewski DM et al. | β | 2005 | β |
| Muscarinic receptor subtype pharmacology and physiology. | Eglen RM | β | 2005 | β |
| Novel neuroprotective effects with O-benzyl derivative of pralidoxime in soman-intoxicated rodents. | Loke WK et al. | β | 2005 | β |
| Reduced cocaine self-administration in muscarinic M5 acetylcholine receptor-deficient mice. | Thomsen M et al. | β | 2005 | β |
| Section I. The cholinergic system. | Smythies J | β | 2005 | β |
| The mechanism of intrinsic amplification of hyperpolarizations and spontaneous bursting in striatal cholinergic interneurons. | Wilson CJ | β | 2005 | β |
| Decreased amphetamine-induced locomotion and improved latent inhibition in mice mutant for the M5 muscarinic receptor gene found in the human 15q schizophrenia region. | Wang H et al. | β | 2004 | β |
| Involvement of cholinergic neuronal systems in intravenous cocaine self-administration. | Smith JE et al. | β | 2004 | β |
| M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related CNS pathologies. | Tzavara ET et al. | β | 2004 | β |
| Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications. | Wess J | β | 2004 | β |
| Nucleus accumbens acetylcholine regulates appetitive learning and motivation for food via activation of muscarinic receptors. | Pratt WE et al. | β | 2004 | β |
| Age-related effects of chlorpyrifos and parathion on acetylcholine synthesis in rat striatum. | Karanth S et al. | β | 2003 | β |
| Alteration in behavioral sensitivity to amphetamine after treatment with oxotremorine. Effect of dose and test environment. | Gralewicz S et al. | β | 2003 | β |
| Altered striatal function and muscarinic cholinergic receptors in acetylcholinesterase knockout mice. | Volpicelli-Daley LA et al. | β | 2003 | β |
| Fulfenamic acid sensitive, Ca(2+)-dependent inward current induced by nicotinic acetylcholine receptors in dopamine neurons. | Yamashita T et al. | β | 2003 | β |
| Novel insights into M5 muscarinic acetylcholine receptor function by the use of gene targeting technology. | Yamada M et al. | β | 2003 | β |
| Novel insights into muscarinic acetylcholine receptor function using gene targeting technology. | Wess J | β | 2003 | β |
| Role of muscarinic receptor subtypes in the constriction of peripheral airways: studies on receptor-deficient mice. | Struckmann N et al. | β | 2003 | β |